Le Lézard
Classified in: Health
Subject: SVY

Wound Debridement Market Worth $6.97 Billion By 2025 | CAGR: 6.10%: Grand View Research, Inc.


SAN FRANCISCO, December 13, 2018 /PRNewswire/ --

The global wound debridement market size is anticipated to reach USD 6.97 billion by 2025 at a 6.10% CAGR during the forecast period, according to a new report by Grand View Research, Inc. Rising cases of injuries that require cleaning and removal of necrotic tissue are leading to increasing demand for wound debridement products.

     (Logo: https://mma.prnewswire.com/media/661327/Grand_View_Research_Logo.jpg )

Wound debridement products help in eliminating or reducing the load of microbes and toxins that inhibit wound healing. Increasing incidence of diabetes and obesity escalates the level of chronic wounds such as diabetic foot ulcers. As per the International Diabetes Federation, the incidence of diabetes is expected to reach 642.0 million by 2040. Prevention of wound infection is one of the major concerns for diabetic patients, making wound debridement vital. With increase in number of diabetics in U.S., demand for wound debridement is on a rise. Burns are the most common wounds and account for around 195,000 deaths annually. This, in addition to rise in awareness regarding the importance of wound debridement, is expected to positively affect the market in the coming years.

Development of advanced wound debridement products is also boosting market growth. For instance, launch of keratin-based wound care products that are used along with dressings have proven to be extremely helpful in wound re-epithelialization. The keratin matrix is absorbed in the wound and eliminates the need for dressing change. Such developments are anticipated to create growth opportunities for market players in the coming years.

Browse full research report with TOC on "Wound Debridement Market Analysis Report By Product (Gels, Ointments & Creams), By Method, By Wound Type (Diabetic Foot, Pressure Ulcers), By End Use, And Segment Forecasts, 2018 - 2025"at: https://www.grandviewresearch.com/industry-analysis/wound-debridement-market

Further Key Findings From the Report Suggest: 

Browse related reports by Grand View Research: 

Grand View Research has segmented the global wound debridement market on the basis of product, method, wound type, end use, and region: 

Explore the BI enabled intuitive market research database, Grand View Compass, by Grand View Research, Inc.

About Grand View Research 

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: +1-415-349-0058
Toll Free: 1-888-202-9519
Email: [email protected]

Web: https://www.grandviewresearch.com


These press releases may also interest you

at 08:30
Assure Holdings Corp. (the "Company" or "Assure") , a provider of intraoperative neuromonitoring ("IONM") and remote neurology services, today announced that it closed the sale of certain assets of its IONM business to MPOWERHealth on March 26, 2024....

at 08:30
SweetWater Brewing Company ("SweetWater Brewing" or "SweetWater"), the largest craft brewer in the Southeast and a subsidiary of Tilray Brands, Inc. , announced today the release of its new Hammer Red Amber Ale, the latest collaboration beer as part...

at 08:25
Aurion Biotech, whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced that it has dosed the first Canadian subject in its Phase 1 / 2 clinical trial (ABA-1, CLARA) of AURN001, a cell...

at 08:16
Canadian health care providers now have access to clinical tools and resources they need to better support older adults experiencing...

at 08:15
VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces that it will be attending the LSX World Congress (29-30 April) and presenting at Bio?quity Europe (12-14 May). The...

at 08:15
Azura Ophthalmics Ltd., a clinical-stage biopharmaceutical company developing a potential new therapeutic class of Ophthalmic Keratolytics for ocular surface diseases, today announced multiple presentations highlighting positive efficacy and safety...



News published on and distributed by: